[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527820":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":26,"overallOfficials":13,"centralContacts":32,"locations":38,"responsibleParty":87,"collaborators":13,"id":89,"slug":13,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":13,"enrollmentInfo":97,"targetDuration":13,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":55,"whyStopped":13,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Centre Francois Baclesse","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Rate of platinum-sensitive ovarian cancer patients according to GIScar HRD signature (classified into HRD or HRP).","Evaluate Platinum-sensitivity patients (defined as absence of disease progression, according to RECIST 1.1 criteria, six months after a first-line platinum-based chemotherapy) correlated with Homologous Recombination status in tumor (HRD : Homologous Recombination deficient \u002F HRP :Homologous Recombination Proficient)","six months after the end of platinum-based chemotherapy",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":6,"description":23,"interventionNames":24},"HRD tests","To determine HRD status on the tumor, 2 different tests will be used concomitantly",[25],"Genetic: tests to determine HRD status",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":13},"GENETIC","tests to determine HRD status","Test Giscar AND test myChoice will be performed.\n\nIf one or two tests identifies a HRD status :\n\na PARP inhibitor treatment may be initiated according to current recommendations",[22],[33],{"name":34,"role":35,"phone":36,"phoneExt":13,"email":37},"Raphaël LEMAN, PhD","CONTACT","33231455050","r.leman@baclesse.unicancer.fr",[39,54,65,76],{"facility":40,"status":41,"city":42,"state":13,"zip":13,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Chu Amiens","NOT_YET_RECRUITING","Amiens","France","FR",{"type":46,"coordinates":47},"Point",[48,49],2.3,49.9,{"lat":49,"lon":48},[52],{"name":53,"role":35,"phone":13,"phoneExt":13,"email":13},"Pierrick THERET, MD",{"facility":5,"status":55,"city":56,"state":13,"zip":13,"country":43,"countryCode":44,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"RECRUITING","Caen",{"type":46,"coordinates":58},[59,60],-0.35912,49.18585,{"lat":60,"lon":59},[63],{"name":64,"role":35,"phone":13,"phoneExt":13,"email":13},"François CHERIFI, MD",{"facility":66,"status":55,"city":67,"state":13,"zip":13,"country":43,"countryCode":44,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Centre Oscar Lambret","Lille",{"type":46,"coordinates":69},[70,71],3.05512,50.63391,{"lat":71,"lon":70},[74],{"name":75,"role":35,"phone":13,"phoneExt":13,"email":13},"Camille PASQUESOONE, MD",{"facility":77,"status":55,"city":78,"state":13,"zip":13,"country":43,"countryCode":44,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Centre Henri Becquerel","Rouen",{"type":46,"coordinates":80},[81,82],1.09932,49.44313,{"lat":82,"lon":81},[85],{"name":86,"role":35,"phone":13,"phoneExt":13,"email":13},"Marianne LEHEURTEUR, MD",{"type":88,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100527820",false,"NCT06152731","HRD Tests for Ovarian cancER","HERO","Inclusion Criteria:\n\n* Patient aged 18-year or more\n* Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer\n* Newly diagnosed advanced (International Federation of Gynecology and Obstetrics \\[FIGO\\] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy\n* Tumor tissue must be available for HRD analyses (FFPE tissue block) and\n\n  * Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)\n  * With sufficient tumour surface area (\\> 25 mm²), with a final cellularity of at least 20%\n* Patient affiliated to an appropriate social security system\n* Patient signed consent form before any trial related activities\n\nExclusion Criteria:\n\n* Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer\n* Non epithelial or borderline ovarian cancer\n* Other tumor, for which the treatment may interfere with the ovarian cancer treatment and\u002For that may have a major impact on prognosis\n* Exclusive palliative setting\n* Patient deprived of liberty or placed under the authority of a tutor","FEMALE","18 Years",{"count":98,"type":99},88,"ESTIMATED","INTERVENTIONAL",[102],"PHASE2","The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy.\n\nTo determine HRD status, 2 separate tests will be performed in the study:\n\n1. Giscar assay : developed by the sponsor\n2. myChoice assay\n\nIf one or two tests identifies a HRD status :\n\na PARP inhibitor treatment may be initiated according to current recommendations",[105],"Ovarian Cancer",[107,108,109,110],"HRD (Homologous Recombination Deficient)","GIScar","myChoice","platinum chemotherapy","2025-09-16",{"date":113,"type":114},"2025-09-17","ACTUAL",{"date":116,"type":114},"2024-02-15",{"date":118,"type":99},"2031-06",{"name":5,"class":6},4]